In this roundtable, perspectives on open access publishing, its importance, and ways of working that should be adopted post-pandemic will be shared. With only three pharma companies mandating that their research is published open access, we discuss why this number is so low and discuss experiences from the companies that have taken this step. From a publisher standpoint, one key barrier to open access has been finding a sustainable publishing model. With increasing numbers of Read & Publish deals and transformative agreements, we explore what approaches could be considered and suggest ways in which we can work towards sustainable open access.
- Discuss the key benefits of publishing open access
- Understand key stakeholder perspectives and barriers to publishing open access
- Learn how barriers to open access may be overcome to achieve a more open future